Adaptive Biotechnologies (ADPT) Accumulated Expenses (2018 - 2026)

Adaptive Biotechnologies has disclosed Accumulated Expenses across 9 years of filings, most recently posting $7.5 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $7.5 million, up 16.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 million (up 16.42% YoY), and the FY2025 annual result was $17.0 million, up 8311.88% from the prior year.
• Accumulated Expenses came in at $7.5 million for Q1 2026 at Adaptive Biotechnologies, down from $17.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $17.0 million in Q4 2025 to a low of $154000.0 in Q4 2023.
• The 5-year median for Accumulated Expenses is $6.7 million (2024), against an average of $7.6 million.
• Across the five-year window, Accumulated Expenses slumped 97.51% in 2022 and jumped 8311.88% in 2025, its largest moves.
• Adaptive Biotechnologies' Accumulated Expenses stood at $233000.0 in 2022, then plunged by 33.91% to $154000.0 in 2023, then jumped by 31.17% to $202000.0 in 2024, then surged by 8311.88% to $17.0 million in 2025, then plunged by 56.07% to $7.5 million in 2026.
• The last three Accumulated Expenses figures came in at $7.5 million (Q1 2026), $17.0 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.